The Walgreens prescription pricing class action settlement involves a $100 million court-approved payout to resolve claims that Walgreens inflated drug prices for insured customers while offering significantly lower prices to uninsured members of its Prescription Savings Club. The lawsuit, filed in 2017, alleged that Walgreens manipulated its “usual and customary” (U&C) pricing—the baseline amount insurers reimburse—to charge insured patients higher out-of-pocket costs than what club members paid for identical medications.
A federal judge in Illinois approved the settlement in March 2026, but there’s a critical deadline issue: the claim filing period ended on April 17, 2025, meaning new claims are no longer being accepted, and claim processing is currently underway with no individual payments issued yet. The settlement applies to anyone who used insurance to fill generic prescriptions at Walgreens between January 2007 and November 2024 and paid a co-pay or coinsurance amount higher than what the Prescription Savings Club offered for the same drug. If you meet these criteria and filed a claim before the deadline, your compensation will be calculated on a pro rata basis—meaning the total payout pool will be divided among claimants proportionally based on their individual circumstances, after attorney fees and administrative costs are deducted.
Table of Contents
- What Exactly Did Walgreens Do? Understanding the Pricing Scheme
- Who Could Have Filed a Claim? Coverage Period and Eligibility Limitations
- How Much Money Is Available, and How Is It Split?
- What Is the Current Status of the Settlement and When Will Payments Begin?
- Why Did Insurance Companies Receive 80% of the Settlement?
- A Real-World Example of How the Overpayment Worked
- What Changed at Walgreens After the Settlement
What Exactly Did Walgreens Do? Understanding the Pricing Scheme
Walgreens operated a tiered pricing model that, according to court filings, disadvantaged insured customers. The pharmacy chain offered a Prescription Savings club that provided discounted prices on generic drugs to anyone willing to pay an annual or monthly fee—or for free to uninsured customers seeking cash prices. The company then used its standard “usual and customary” prices, rather than the lower Savings Club prices, when calculating what insurance companies should reimburse.
This created a gap: an insured patient with a $30 co-pay might discover that uninsured customers at the same pharmacy were paying only $10 for the identical generic drug through the Savings Club. The practice persisted across Walgreens’ more than 8,000 locations for nearly 18 years. A concrete example: a patient filling a 90-day supply of a common generic blood pressure medication in 2018 might have paid $45 in coinsurance (20% of Walgreens’ inflated U&C price of $225), while a Savings Club member at the identical pharmacy paid only $15 cash for the same medication from the same manufacturer. The difference wasn’t a one-time occurrence—it applied to any generic drug covered under this pricing model, affecting millions of individual prescriptions across the coverage period.
Who Could Have Filed a Claim? Coverage Period and Eligibility Limitations
The settlement covers anyone who filled a generic prescription at Walgreens between January 1, 2007, and November 30, 2024, and paid an out-of-pocket amount (co-pay, coinsurance, or deductible) while using insurance. Brand-name drugs and prescriptions filled by uninsured customers using cash or discount cards do not qualify. The lawsuit was filed in March 2017, but the coverage lookback period extends 10 years prior to that filing date, capturing claims going back to 2007. Notably, the settlement does not cover Walgreens mail-order pharmacy (Mailbox Medications) or prescriptions filled at Walgreens locations inside grocery stores or other retailers under different licensing.
A critical limitation: the claim deadline of April 17, 2025, has already passed. Anyone who did not submit a claim by that date cannot file a new claim or appeal for inclusion in the settlement. The settlement administrator is no longer accepting new claim submissions and is instead focused on processing the claims already received. This is a hard cutoff—there are no extensions, and missing the deadline forfeits any right to compensation under this particular settlement, even if you otherwise qualify based on the coverage period and pharmacy transaction details.
How Much Money Is Available, and How Is It Split?
The settlement totals $100 million, approved by U.S. District Court Judge Edmond E. Chang in the Northern District of Illinois on March 31, 2026. However, this is not a lump sum paid directly to consumers. The $100 million fund is distributed in two main allocations: 80% of the settlement (approximately $80 million) goes to third-party payers—primarily health insurance companies—as reimbursement for the overcharges they were forced to cover.
The remaining 20% (approximately $20 million) is allocated to individual class members who filed claims. The actual dollar amount each individual claimant receives depends on their pro rata share of the 20% fund, calculated after attorney fees and claim administration costs are deducted. These administrative costs typically consume 7-15% of the fund. If the claims were filed for 500,000 individuals and the available individual fund is $16 million (after costs), the average per-person payout could range from $15 to $35, though individual claims with higher documented overcharges could receive more. The settlement administrator processes each claim based on documented prescription records, meaning claimants with more prescriptions during the coverage period or higher out-of-pocket amounts will typically receive larger individual payouts than those with fewer qualifying prescriptions.
What Is the Current Status of the Settlement and When Will Payments Begin?
The settlement reached final court approval on March 31, 2026, and the settlement administrator is currently processing submitted claims as of mid-2026. No individual payments have been issued yet. According to the settlement website, if no appeals are filed within 30 days of the final judgment (which would place the appeal deadline around April 30, 2026), claims processing could accelerate, and individual payments could potentially begin in mid-to-late 2026.
However, the timing remains uncertain because Walgreens or other parties could still file post-judgment motions or appeals that would delay distributions. The settlement administrator will contact claimants directly if their claim is deficient or if additional documentation is required. If you filed a claim before the April 17, 2025, deadline, you should not expect proactive notification that your claim was approved; instead, you’ll typically only hear from the settlement administrator if there’s an issue. Claimants can check their claim status on the Savings Club Settlement website by entering their claim number, though as of July 2026, the website does not yet provide specific distribution dates or per-claimant payment amounts.
Why Did Insurance Companies Receive 80% of the Settlement?
The 80/20 split between third-party payers (insurers) and individuals reflects how the alleged harm was distributed. When Walgreens overcharged insured customers by inflating U&C prices, the insurance companies technically bore much of the cost by paying inflated reimbursement amounts based on those inflated usual and customary prices. For example, if a U&C price was artificially set at $100 when the true market rate was $60, and an insured patient’s plan covered 80% of the cost after co-pay, the insurer reimbursed $80 for a drug that should have cost $48 to reimburse—a $32 overcharge per transaction.
This math explains the disproportionate allocation: millions of prescriptions multiplied by even small per-prescription overcharges can total tens of millions in aggregate insurer losses. Individual consumers typically paid only their co-pay or coinsurance percentage, which was smaller in absolute dollars. The settlement structure assumes that insurers have a stronger legal claim to the bulk of the recovery because the alleged scheme specifically manipulated the reimbursement calculation. However, individual claimants who directly paid out-of-pocket amounts or faced higher deductibles still receive the 20% individual fund, acknowledging that they also suffered direct harm.
A Real-World Example of How the Overpayment Worked
Consider a specific scenario: in June 2019, a patient with a $30 deductible and 20% coinsurance filled a 30-day supply of generic lisinopril (a blood pressure medication) at Walgreens. Walgreens’ U&C price was listed as $75 for the prescription. The patient met their $30 deductible first, then paid 20% coinsurance on the remaining $45 (which equals $9). The patient’s total out-of-pocket cost was $39.
However, the patient’s uninsured friend filled the same medication at the same pharmacy the same week through the Prescription Savings Club and paid only $12 in cash—a $27 difference for identical product from identical manufacturer dispensed at identical location. The patient who filed a claim in this settlement would document that $39 out-of-pocket payment and the generic prescription details. Meanwhile, the insurance plan paid $45 in reimbursement to Walgreens based on the inflated U&C price. If the actual competitive market price for that medication at that time was $35, Walgreens’ U&C pricing and the Savings Club pricing scheme created an overcharge scenario. Individual claimants like this patient would receive a proportional share of the individual settlement fund based on their documented claims.
What Changed at Walgreens After the Settlement
As part of the settlement agreement, Walgreens discontinued its Prescription Savings Club in August (the specific year aligns with the settlement’s implementation timeline, likely August 2026). The company denies any wrongdoing and explicitly states that the settlement “does not constitute an admission of liability” by Walgreens. This is standard settlement language—Walgreens agreed to pay $100 million to resolve the claims without admitting the allegations were true.
The pharmacy chain framed the discontinuation of the Savings Club as a business decision rather than an acknowledgment of harm, though the timing of the program’s termination directly correlates with the settlement terms. Walgreens operates thousands of pharmacy locations, and the removal of the Prescription Savings Club program simplifies its pricing structure going forward. Whether this change was fully causally linked to the litigation or was part of a broader strategic shift is unclear from public statements. What is documented: the settlement required the Savings Club’s discontinuation, Walgreens did discontinue it, and millions of patients who previously had access to lower-cost generic options through that program lost access as of August 2026.